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Abstract
The objective of the research was to determine the characteristics of arterial stiffness and cardiovascular risk in patients
with co-existence of asthma and chronic obstructive pulmonary disease.
Materials and methods. The study included patients with symptoms of chronic obstructive pulmonary disease, those with
asthma and chronic obstructive pulmonary disease and the group of apparently healthy individuals.
Results. In patients with obstructive lung disease, the parameters of vascular stiffness and central blood pressure reflecting
the degree of cardiovascular risk were significantly higher as compared to those in apparently healthy individuals. They
were significantly elevated in patients with chronic obstructive pulmonary disease and asthma-chronic obstructive pulmonary
disease overlap. The indicators of central blood pressure were significantly higher in patients with asthma-chronic obstructive
pulmonary disease overlap and more pronounced bronchial obstruction, and in patients with more obvious symptoms of
obstructive pathology. Excess body weight or obesity had a strong and pronounced effect on the parameters of central
blood pressure in patients with asthma-chronic obstructive pulmonary disease overlap. In patients with a comorbidity, a
reliable correlation between the indicator of the presence of pulmonary hyperinflation and the degree of arterial stiffness was
revealed.
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Problem statement and analysis of the
recent research
Both asthma and chronic obstructive pulmonary disease (COPD)
are common among the population. Although they have dif-
ferent specific characteristics, some patients develop the signs
of both diseases, and they have asthma-COPD overlap (ACO).
To diagnose ACO is a challenging task considering the clinical
similarity of two diseases and various phenotypes [1]. COPD
is a disease that can be prevented and treated, and is character-
ized by persistent airflow limitation that is usually progressive
being associated with an enhanced chronic inflammatory re-
sponse of the lungs to harmful particles and gases [2]. In
this definition, the main emphasis is on bronchopulmonary
manifestations. However, in recent years, non-pulmonary
manifestations of COPD, such as systemic inflammation, mus-
cle dysfunction, cardiovascular disorders, body weight loss,
osteoporosis, anemia have been increasingly discussed [3].
A number of epidemiological studies have shown that
the leading cause of mortality in mild to moderate COPD is
not respiratory failure, but cardiovascular pathology, namely
coronary heart disease (CHD) and heart failure (HF) [4-7]; in
such patients, the risk of cardiovascular death accounting for
nearly 50% of all deaths increases by 2-3 times [5].
Increased vascular stiffness being one of the markers of
subclinical atherosclerosis is associated with the development
of cardiovascular complications (myocardial infarction, stroke,
HF, kidney disease, and high rates of overall mortality) [8-11].
Changes in elastic vessels (the aorta and pulmonary artery)
play a significant role in the pathogenesis of hypertension.
Normally, the elastic properties of these blood vessels facili-
tate absorption stroke volume and can transfer large part of
energy reduction during cardiac diastole. This leads to the
reduction in aortic systolic blood pressure (SBP) and the in-
crease in diastolic blood pressure (DBP), thereby decreasing
damaging effect of pulse wave on the blood vessels in the
brain, heart and kidneys and improving blood flow to these
organs. Pulse wave velocity (PWV) reflects central and pe-
ripheral arterial stiffness. The determination of PWV is an
informative and safe method of non-invasive assessment of
central vascular stiffness. In particular, PWV in elastic arter-
ies is the current gold standard for evaluating arterial stiffness
and a strong predictor of future cardiovascular events and
the overall death rate being of great importance in clinical
research and general practice [12, 13, 14].
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PWV is known to be more important than SBP marker of
increased cardiovascular risk. It is an independent predictor of
all-cause and cardiovascular mortality, particularly in patients
with CHD and hypertension [12, 13, 14, 15, 16]. Previous
studies have demonstrated increased arterial stiffness in pa-
tients with COPD compared to ex-smokers without bronchial
obstruction and apparently healthy individuals irrespective of
smoking status [17, 18, 19].
Previous studies have demonstrated that during the 9-year
follow-up period, in patients with persistent asthma, the risk
of cardiovascular events, namely myocardial infarction, heart
failure and cardiovascular death increased by 60% as com-
pared to individuals without asthma. In patients with persis-
tent asthma, the levels of C-reactive protein and fibrinogen
were significantly higher as well that indicated the relation
between the inflammatory processes and cardiovascular dis-
eases in asthma [20, 21]. These preliminary studies have
pointed out increased arterial stiffness in patients with asthma
as compared to healthy individuals [22, 23].
The augmentation index (AIx) is a more indirect indicator
of arterial stiffness as compared to PWV and reflects the
combined effect of PWV in large arteries, peripheral wave
reflection and vascular properties. The assessment of the AIx
is simpler as compared to the determination of PWV [24, 25].
Previous studies have demonstrated independent prognostic
features of this index as a predictor of acute cardiovascular
events [26]. The AIx varies depending on heart rate (HR); the
AIx adjusted to a standard heart rate of 75 bpm (AIx75) is
commonly used (AIx75). Previous studies have demonstrated
that in patients with COPD, the AIx was higher as compared
to apparently healthy individuals [17, 27].
Left ventricular (LV) ejection duration (ED) is the ratio of
ventricular systole to the total duration of the cardiac cycle. In
patients with LV systolic dysfunction, according to previous
studies, ED rate was higher compared to patients with LV
diastolic dysfunction. Subendocardial viability ratio (SEVR)
reflects the state of subendocardial viability and in presence
of subendocardial ischemia it falls below 50% [28].
According to previous studies, there have been revealed
significant properties of central pressure, in particular, central
SBP, in predicting the development of LV hypertrophy, LV
systolic dysfunction, left atrial dilatation, the onset of atrial
fibrillation and LV diastolic dysfunction [29, 30]. The results
of the Conduit Artery Function Evaluation (CAFE) study,
a substudy of the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT) have confirmed that central aortic pressure
is a stronger predictor of stroke and CHD complications as
compared to peripheral blood pressure (BP) in the brachial
artery [31].
The objective of the research was to determine the char-
acteristics of arterial stiffness and cardiovascular risk in pa-
tients with co-existence of asthma and COPD.
1. Materials and methods
The study included patients with symptoms of ACO over the
age of 30 years. ACO diagnosis was verified by the Global
Initiative for Asthma (GINA) criteria and the Global Initiative
for Obstructive Lung Disease (GOLD) criteria [32-34]. All
the patients had persistent, albeit variable symptoms of asthma
and COPD. The patients’ condition was stable; none of them
had exacerbations 2 months prior to the study. The study
included patients with asthma and COPD and the group of
apparently healthy individuals as well. The most common
comorbid conditions in patients with ACO were found to be
hypertension (65%), CHD (37%), diabetes mellitus (DM)
(12%), and gastrointestinal diseases (19%). Characteristics of
patients are given in Table 1.
All the patients underwent the following examinations:
height and weight measurements, determination of body mass
index (BMI), spirometry, whole body plethysmography and
pulse wave analysis.
Spirometry was performed using the MasterScreen Pneumo
system (Cardinal Health, Germany). To determine total air-
way resistance (Rtot), total lung capacity (TLC), intrathoracic
gas volume (ITGV) that includes residual volume (RV) and
expiratory reserve volume (ERV), whole body plethysmog-
raphy was performed using the Master Screen PFT system
(Cardinal Health, Germany).
PWV measurements were performed using the Sphyg-
moCor Px system (Atcor Medical Blood Pressure Analysis
System, Sydney, Australia). PWV was evaluated between
the carotid and femoral artery with the participant lying in
the supine position. Pulse measurements were performed
non-invasively using the SphygmoCor probe over the carotid
and femoral artery with simultaneous ECG recording. The
distance from the carotid artery to the femoral artery was mea-
sured directly between each artery location and the supraster-
nal notch and the values were entered in the SphygmoCor
software database. The parameters of central aortic hemody-
namics were measured using radial artery applanation tonom-
etry.
In order to evaluate the elastic properties of elastic arteries,
carotid-femoral artery PWV (PWVe) was determined; in order
to evaluate the elastic properties of muscular arteries carotid-
radial PWV (PWVm) was measured.
There were determined the following parameters: central
SBP, central DBP, central pulse pressure (PP), augmentation
pressure (AP), heart rate normalized AIx (AIx75), LVED,
SEVR, LV end-systolic pressure (ESP).
The accumulation of data and their mathematical pro-
cessing were carried out using licensing software products
included in the package Microsoft Office Professional 2007
Russian Academic OPEN No Level No 43437596. Statistical
processing was performed using mathematical and statistical
functions of MS Excel. The studied parameters were evalu-
ated using the mean value (M), the error of the mean value
(m), test of statistical significance (t), significance value (p),
followed by the comparison using the Student’s t-test and the
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Table 1. Characteristics of patients
Indices Asthma (n=17) COPD (n=10) ACO (n=111)
Gender, (n) 14 women, 3 men 4 women, 6 men 54 women, 57 men
Age, years 51.0±1.75 68.3±2.7 58.13±0.93
BMI, kg/m2 30.32±1.52 30.4±1.7 28.86±0.49
Ex-smokers (%) 71 60 64
Smokers (%) 29 40 36
Asthma severity degree
mild, (%) 23 7
moderate, (%) 65 80
severe, (%) 12 13
Groups of patients with COPD
A (%) 20 14
B (%) 20 21
C (%) 20 21
D (%) 40 44
GOLD COPD stage
1, (%) 50 32
2, (%) 10 56
3, (%) 30 11
4, (%) 10 1
Mann-Whitney U test depending on the type of data distri-
bution. Correlation analysis was performed calculating the
Pearson correlation coefficient.
2. Results and discussion
Central SBP, PP, ESP and PWVm were higher in patients
with asthma as compared to the control group. Central SBP,
DBP, PP, AP, AIx, ESP and PWVe were significantly higher
in patients with COPD. Moreover, in these patients, the rate
of PWVe was significantly higher as compared to both the
control group and patients with asthma.
In patients with ACO, central SBP, DBP, PP, ED, SEVR,
ESP, and PWVe were significantly different from those in
apparently healthy individuals. When comparing the indices
in patients with COPD and those with ACO, significantly
higher ESP and PWVe were found in patients with COPD.
SERV, which is an index characterizing the state of coro-
nary perfusion, was significantly lower in patients with ACO
as compared to the control group. Therefore, a significant dete-
rioration of coronary perfusion was observed in patients with
co-existent pathology, although the index remained within the
normal range. The data are presented in Table 2.
The increase in central SBP, PP and AIx75 indicates an
increase in cardiovascular risk. The value of central PP charac-
terizes the degree of pulse wave activity effect on the vessels
of target organs. Central PP is an independent predictor of
cardiac and cerebral events. Thus, in comorbid pathology and
COPD, cardiovascular risk and arterial stiffness were more
pronounced as compared to those in healthy individuals and
patients with asthma.
In patients with COPD, there was found a higher degree
of arterial stiffness as compared to apparently healthy indi-
viduals. In guidelines for management of hypertension, arte-
rial stiffness is included in the number of target organs that
are investigated for determining subclinical organ damage in
hypertension, and factors having a significant effect on the
prognosis of patients. Thus, in previous studies, there was
found a relation between PWV and stroke development in hy-
pertension. The increase in PWV by 1 m/s increased all-cause
and cardiovascular mortality by 15% [11, 13, 35].
Potential factors affecting the development of central hemo-
dynamic disturbances and increased arterial stiffness in pa-
tients with obstructive lung disease are the effects of smoking,
bronchial obstruction, hypodynamia, age-related factors, sys-
temic inflammation, and oxidative stress which are typical
for this disease. The presence of systemic inflammation and
oxidative stress in such patients may explain the appearance of
numerous comorbidities. The results of previous studies have
demonstrated the relation between systemic inflammation and
arterial stiffness [18, 19].
The next task of our research was to evaluate arterial
stiffness and the state of central hemodynamics in patients
with ACO depending on the degree of bronchial obstruction.
Patients with ACO and higher degree of bronchial ob-
struction (GOLD 2 and GOLD 3, 4) had higher indicators of
central SBP, DBP and PP: in patients with GOLD 2 COPD,
they were significantly higher compared to those with GOLD
1 COPD. PWVm was the highest in patients with a low de-
gree of bronchial obstruction, while PWVe was the highest in
patients with more pronounced bronchial obstruction. These
features indicated a more pronounced cardiovascular risk in
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Table 2. Indices of vascular stiffness and central BP in patients with asthma, COPD, ACO and healthy individuals
Indices Apparently healthy
individuals
Asthma COPD ACO
(n = 35) (n=17) (n=10) (n=111)
Central SBP, mm Hg 110.97±1.69 124.29±3.82** 127.8±2.07** 123.24±1.32**
Central DBP, mm Hg 80.14±1.01 85.76±2.19 85.4±2.18* 85.15±0.86*
Central PP, mm Hg 30.83±1.07 39.59±2.71** 46.6±4.7** 39.5±1.01**
ED, ms 322.51±3.59 308.65±7.12 297.9±6.17* 309.82±2.9*
ED, % 35.8±0.84 36.0±1.11 35.3±1.37 36.66±0.44
AP, mm Hg 7.97±0.94 11.24±1.27 12.3±1.08* 10.68±0.57
AIx75, % 20.34±2.06 25.82±1.5 27.1±1.54* 24.99±1.01
SEVR, % 158.74±4.9 154.88±8.52 156.6±10.17 149.67±2.82**
ESP, mm Hg 102.4±1.77 113.47±3.54* 117.1±1.93** 111.26±1.58* β
PWVm, m/s 3.05±0.13 4.25±0.44* 3.69±0.37 3.69±0.1
PWVe, m/s 3.02±0.12 4.0±0.29 5.63±0.34**γγ 4.88±0.19* γ β
Note.
* p <0.05;
** p <0.01 compared to the control group;
γ p <0.05; γγ p <0.01 compared to patients with asthma;
β p <0.05; ββ p <0.01 compared to patients with COPD.
patients with ACO and a high degree of bronchial obstruction.
According to previous studies, bronchial obstruction is an
independent predictor of arterial stiffness. Previously, there
was a significant correlation between forced expiratory vol-
ume in the first one second (FEV1), forced vital capacity
(FVC) and PWVe in men with hypertension. One of the poten-
tial factors of the reduction in pulmonary function and high
vascular stiffness may be change in the elastic properties of
the alveoli and the vascular wall [19]. The data are presented
in Table 3.
When comparing the indices of vascular stiffness in dif-
ferent clinical groups of patients with ACO (GOLD classifica-
tion), in patients with more pronounced symptoms (Group B
and Group D), there were found significantly higher levels of
central PP and AIx75 and significantly lower level of SEVR
as compared to patients with minor symptoms (Group A and
Group C) (p<0.05). The data are demonstrated in Fig. 1.
Increased arterial stiffness, central BP, and higher cardio-
vascular risk were found in patients with severer course of
ACO.
The importance of smoking as a risk factor for developing
cardiovascular disease and premature death has been proven
in numerous studies and is universally accepted. According to
preliminary data, tobacco smoking doubles the risk of devel-
oping angina pectoris and myocardial infarction and increases
the risk of sudden cardiac death by almost 5 times. Approxi-
mately one-third of deaths from coronary heart disease was
found to be associated with tobacco smoking [36, 37].
The next task of our study was to determine the effect
of active tobacco smoking on central BP and the state of the
vascular wall in patients with ACO. In active smokers with
ACO, the level of central DBP was significantly higher, while
ED and AIx75 were lower. Thus, the negative impact of
smoking on the indices of central BP was noted. There were
no convincing data on the effect of active tobacco smoking on
the parameters of arterial stiffness in patients with ACO. The
data are shown in Table 4.
Obesity is the most common metabolic disease in the
world. Numerous studies have proven the independent influ-
ence of excess body weight and obesity on the development
of hypertension, myocardial hypertrophy, dyslipidemia and
DM. The presence of obesity increases the risk of coronary
heart disease, ischemic stroke and death from cardiovascular
disease [38, 39].
The objective of this study was to detect the effect of body
mass on the parameters of central BP and vascular properties
in patients with ACO. Most patients with ACO included in
our study had metabolic disorders of varying degrees of sever-
ity (30% of patients had excess body weight and 45% had
obesity).
In patients with ACO and excess body weight, central
DBP was significantly higher in comparison with those having
normal body weight. In patients with obesity, the indicators
of central SBP, DBP were the highest, and ED was lower as
compared to patients with normal body mass. In patients with
obesity, the index of SEVR was significantly lower in compar-
ison with patients having excess body weight. Therefore, the
negative effect of metabolic disorders on the parameters of
central BP and the overall cardiovascular risk in patients with
ACO was revealed. The data are presented in Table 5. One
of the signs of the severity of bronchial obstructive disease
clinical course is the development of pulmonary hyperinfla-
tion (i.e., an increase in the residual volume). The ratio of
the residual volume to total lung capacity (RV/TLC) is an
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Table 3. Indices of arterial stiffness and central BP in patients with ACO and different degrees of bronchial obstruction
Indices GOLD 1 (n=36) GOLD 2 (n=62) GOLD 3, 4 (n=13)
Central SBP, mm Hg 119.08±2.45 125.24±1.76* 125.23±3.04
Central DBP, mm Hg 82.75±1.69 86.58±1.09* 85.0±2.23
Central PP, mm Hg 36.33±1.27 40.81±1.5* 42.0±3.18
ED, ms 317.36±5.27 304.77±3.87* 313±7.67
ED, % 36.14±0.83 37.03±0.57 36.31±1.34
AP, mm Hg 10.11±1.13 10.71±0.73 12.15±1.46
AIx75, % 22.97±2.04 25.82±1.31 26.69±2.08
SEVR, % 154.19±5.25 147.03±3.8 149.69±7.34
ESP, mm Hg 105.26±3.73 114.27±1.64* 113.54±2.81*
PWVm, m/s 3.83±0.23 3.72±0.13 3.19±0.21* γ
PWVe, m/s 4.49±0.26 4.98±0.28 5.55±0.68
Note.
*p <0.05;
** p <0.01 as compared to patients with GOLD 1 COPD;
γ p <0.05;
γγ p <0.01 compared to patients with GOLD 2 COPD.
Figure 1. Indices of arterial stiffness and central BP in patients with ACO
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Table 4. Indices of arterial stiffness and central BP in patients with ACO depending on smoking status
Indices Ex-smokers (n=71) Active smokers (n=40)
Central SBP, mm Hg 122.25±1.72 125.0±2.07
Central DBP, mm Hg 83.75±1.14 87.65±1.2*
Central PP, mm Hg 39.61±1.17 39.3±1.92
ED, ms 315.42±3.84 299.88±3.94**
ED, % 36.52±0.52 36.9±0.81
AP, mm Hg 11.79±0.72 8.73±0.87**
AIx75, % 26.83±1.19 21.78±1.76*
SEVR, % 150.34±3.62 148.48±4.6
ESP, mm Hg 109.86±2.21 113.75±1.96
PWVm, m/s 3.67±0.15 3.73±0.14
PWVe, m/s 4.92±0.26 4.8±0.25
Note.
* p <0.05;
** p <0.01 as compared to ex-smokers
Table 5. Indices of arterial stiffness and central BP in patients with ACO depending on BMI
Indices Patients with normal body
weight
Patients with excess body
weight
Obese patients
(n = 28) (n = 33) (n = 50)
Central SBP, mm Hg 119.25±2.68 122.27±2.69 126.12±1.78*
Central DBP, mm Hg 81.11±1.72 85.48±1.66* 87.2±1.18**
Central PP, mm Hg 38.14±1.8 39.15±1.98 40.48±1.56
ED, ms 320.68±6.11 309.3±6.11 304.08±3.63*
ED, % 36.11±1.02 35.85±0.75 37.5±0.62
AP, mm Hg 11.18±0.88 11.03±1.12 10.18±0.92
AIx75, % 25.39±1.8 25.84±2.21 24.22±1.45
SEVR, % 152.75±6.58 156.06±5.56 143.72±3.52 γ
ESP, mm Hg 107.64±2.68 112.82±2.56 112.27±2.71
PWVm, m/s 3.45±0.18 3.74±0.22 3.8±0.17
PWVe, m/s 4.61±0.38 5.04±0.37 4.92±0.27
Note.
* p <0.05;
** p <0.01 compared to patients with normal body weight;
γ p <0.05;
γγ p <0.01 compared to patients with excess body weight.
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important prognostic marker, and its increase by more than
73% is a sign of a high risk of death [40]. There was a reliable
correlation between the RV/TLC ratio and the AIx in patients
with ACO (r = 0.37; p <0.05) (Fig. 2). Therefore, in patients
with ACO, one of the main indicators of arterial stiffness was
associated with the development of pulmonary hyperinfla-
tion. This association may be the result of systemic effects of
ACO (systemic inflammation, hypoxia, oxidative stress, etc.),
the impact of negative environmental factors, changes in the
elastic properties of the lungs and the vascular wall [18].
3. Conclusions
In patients with bronchial obstructive pathology, the parame-
ters of vascular stiffness and central BP reflecting the degree
of cardiovascular risk were significantly higher compared to
those in apparently healthy individuals. They were signifi-
cantly elevated in patients with COPD and ACO.
The indicators of central BP were significantly higher
in patients with ACO and more pronounced bronchial ob-
struction, and in patients with more obvious symptoms of the
underlying disease.
Excess body weight or obesity had a strong and pro-
nounced effect on the parameters of central BP in patients
with ACO.
In patients with a comorbidity, a reliable correlation be-
tween the indicator of the presence of pulmonary hyperinfla-
tion and the degree of arterial stiffness was revealed.
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